Urocanic acid - Herantis Pharma

Drug Profile

Urocanic acid - Herantis Pharma

Alternative Names: Ci-UCA Emulsion Cream; Cis-UCA; Cis-UCA Eye Drops; ProtoCure; UCA-001; UCA-002

Latest Information Update: 07 Feb 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator BioCis Pharma
  • Developer Herantis Pharma
  • Class Acrylates; Antineoplastics; Imidazoles; Immunotherapies; Skin disorder therapies; Small molecules
  • Mechanism of Action Immunosuppressants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes
  • Available For Licensing Yes - Atopic dermatitis; Dry eyes

Highest Development Phases

  • Phase II Dry eyes
  • Suspended Atopic dermatitis
  • No development reported Bladder cancer; Interstitial cystitis
  • Discontinued Plaque psoriasis

Most Recent Events

  • 07 Feb 2017 Phase-II development for Dry eyes is ongoing in USA (Ophthalmic, drops)
  • 15 Dec 2016 Biomarkers information updated
  • 12 Oct 2015 Urocanic acid - Herantis Pharma is available for licensing-http://herantis.com/wp-content/uploads/2015/09/Herantis_NLS_2015.pdf
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top